摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-hydroxy-2-(3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-1-(3-methyl-butyl)-1H-benzoimidazole-5-carboxamidine | 554458-47-8

中文名称
——
中文别名
——
英文名称
N-hydroxy-2-(3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-1-(3-methyl-butyl)-1H-benzoimidazole-5-carboxamidine
英文别名
N'-hydroxy-1-(3-methylbutyl)-2-[(2-oxo-3-propan-2-ylbenzimidazol-1-yl)methyl]benzimidazole-5-carboximidamide
N-hydroxy-2-(3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-1-(3-methyl-butyl)-1H-benzoimidazole-5-carboxamidine化学式
CAS
554458-47-8
化学式
C24H30N6O2
mdl
——
分子量
434.541
InChiKey
ZMNJNFCTZRRNNG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    100
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-hydroxy-2-(3-isopropyl-2-oxo-2,3-dihydro-benzoimidazol-1-ylmethyl)-1-(3-methyl-butyl)-1H-benzoimidazole-5-carboxamidine 在 BF3.OEt2 作用下, 以 原甲酸三甲酯 为溶剂, 以53%的产率得到1-isopropyl-3-[1-(3-methyl-butyl)-5-[1,2,4]oxadiazol-3-yl-1H-benzoimidazol-2-ylmethyl]-1,3-dihydro-benzoimidazol-2-one
    参考文献:
    名称:
    Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
    摘要:
    本发明涉及抗病毒化合物,其制备方法及其组合物,以及在治疗病毒感染中的应用。更具体地,该发明提供了用于治疗呼吸道合胞病毒感染的杂环取代2-甲基苯并咪唑衍生物。
    公开号:
    US20030207868A1
  • 作为产物:
    参考文献:
    名称:
    Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity
    摘要:
    Extensive SAR studies and optimization of ADME properties of benzimidazol-2-one derivatives led to the identification of BMS-433771 (3) as an orally active RSV fusion inhibitor. In order to extend the structure-activity relationships for this compound series, substitution of the benzimidazole ring was examined with a view to establishing additional productive interactions between the inhibitor and functionality present in the proposed binding pocket. Amongst the compounds synthesized, the 5-aminomethyl analogue 10aa demonstrated potent antiviral activity towards wild-type RSV and retained excellent inhibitory activity towards a virus that had been developed to express resistance to BMS-433771 (3), data consistent with an additional productive interaction between the inhibitor and the fusion protein target. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.05.102
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1461035A2
    公开(公告)日:2004-09-29
  • EP1461035A4
    申请人:——
    公开号:EP1461035A4
    公开(公告)日:2005-04-06
  • US6919331B2
    申请人:——
    公开号:US6919331B2
    公开(公告)日:2005-07-19
  • [EN] SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS<br/>[FR] 2-METHYL-BENZIMIDAZOLE SUBSTITUES EN TANT QU'AGENTS ANTIVIRAUX DU VIRUS RESPIRATOIRE SYNCYTIAL
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2003053344A2
    公开(公告)日:2003-07-03
    The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
  • Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
    申请人:——
    公开号:US20030207868A1
    公开(公告)日:2003-11-06
    The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.
    本发明涉及抗病毒化合物,其制备方法及其组合物,以及在治疗病毒感染中的应用。更具体地,该发明提供了用于治疗呼吸道合胞病毒感染的杂环取代2-甲基苯并咪唑衍生物。
查看更多